Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines (Q27852814)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines	scientific article

Statements

scholarly article

1 reference

13 November 2016

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines (English)

1 reference

13 November 2016

Carleen Cullinane

object named as

Carleen Cullinane

9

0 references

object named as

Grant A McArthur

19

0 references

Alexander Dobrovic

object named as

Alexander Dobrovic

15

0 references

object named as

Stephen B Fox

11

0 references

Karen E Sheppard

object named as

Karen E Sheppard

20

0 references

14

object named as

Nicholas Jene

0 references

author name string

Richard J Young

1

0 references

Kelly Waldeck

2

0 references

Claire Martin

3

0 references

Jung H Foo

4

0 references

Donald P Cameron

5

0 references

Laura Kirby

6

0 references

Hongdo Do

7

0 references

Catherine Mitchell

8

0 references

Wendy Liu

10

0 references

Ken Dutton-Regester

12

0 references

Nicholas K Hayward

13

0 references

Richard B Pearson

16

0 references

James G Christensen

17

0 references

Sophia Randolph

18

0 references

publication date

July 2014

0 references

Pigment Cell & Melanoma Research

0 references

27

0 references

590-600

0 references

4

0 references

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Targeting cell cycle and hormone receptor pathways in cancer.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

A high-throughput panel for identifying clinically relevant mutation profiles in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Spontaneous and UV radiation-induced multiple metastatic melanomas in Cdk4R24C/R24C/TPras mice.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Germline p16 mutations in familial melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Tailoring to RB: tumour suppressor status and therapeutic response

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12228

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27852814&oldid=1858096111"